BD Wins Vizient Innovative Technology Contract for the CentroVena One™ Insertion System

0
82

Key Takeaways

  • BD’s CentroVena One™ Insertion System received an Innovative Technology contract from Vizient, recognizing its potential to improve healthcare delivery.
  • The all‑in‑one design integrates guidewire, needle, syringe and catheter, cutting procedural steps by ~30 % and maximum procedure time by ~50 % versus traditional central venous catheter (CVC) placement.
  • Safety‑focused features aim to reduce contamination, air/guidewire embolism, needlestick injury, and clinician blood exposure.
  • The contract was awarded after evaluation by Vizient’s client‑led councils, which represent over $156 billion in annual purchasing volume across diverse healthcare settings.
  • BD emphasizes that the innovation addresses a clear clinical need for a simpler, more standardized central line insertion process that enhances efficiency and patient safety.

Overview of the Announcement
On June 23, 2026, BD (Becton, Dickinson and Company) announced that its BD® CentroVena One™ Insertion System had been awarded an Innovative Technology contract by Vizient®, the nation’s largest provider‑driven healthcare performance improvement company. The press release, distributed via PRNewswire from Franklin Lakes, N.J., highlights that the contract recognizes products capable of driving meaningful improvements in healthcare delivery. Vizient’s decision followed a rigorous review by hospital experts serving on its client‑led councils, underscoring the system’s perceived value to a broad spectrum of healthcare providers.

What the CentroVena One™ System Is
The CentroVena One™ Insertion System is described as the first and only all‑in‑one central venous catheter (CVC) insertion system. It integrates the guidewire, needle, syringe, and catheter into a single, cohesive device. By consolidating these components, the system is designed to simplify the central line placement process, reduce the number of separate parts clinicians must handle, and thereby lower the likelihood of procedural errors or contamination that can arise when multiple components are exchanged.

How It Streamlines Workflow
According to BD, the all‑in‑one design translates into concrete efficiency gains: approximately 30 % fewer procedural steps and a 50 % reduction in maximum procedure time when compared with standard CVC insertion techniques. These figures are derived from a head‑to‑head simulation study (N = 49) published in The Journal of Emergency Medicine in December 2025. While the company cautions that simulation results may not fully mirror actual clinical performance, the data suggest a notable potential to accelerate catheter placement and free up clinical staff for other patient‑care tasks.

Safety Enhancements Built Into the Design
Beyond workflow improvements, CentroVena One™ incorporates several safety‑focused design elements. The integrated system aims to reduce contamination risk by limiting the number of times the catheter tract is exposed to the external environment. It also seeks to protect against complications such as air embolism, guidewire embolism, needlestick injury, and clinician blood exposure. By providing a more consistent and controlled insertion process, the system supports safer patient outcomes and reduces occupational hazards for healthcare workers.

Executive Perspective from BD
Eric Borin, worldwide president of Medication Delivery Solutions at BD, emphasized that the Vizient contract validates the innovation behind CentroVena One™ and its potential to redefine central line placement. He noted that clinicians have been asking for a simpler, more standardized approach to central line insertion, which would enable them to work more efficiently while supporting safer patient care. Borin expressed excitement about bringing this innovation to a broader base of Vizient clients, clinicians, and the patients they serve.

Vizient’s Evaluation Process
Kelly Flaharty, associate vice president of contract operations for Vizient, explained that the contract was awarded after a thorough evaluation by Vizient’s client‑led councils. These councils, composed of hospital experts, assess products for their capacity to offer meaningful differentiation in today’s competitive healthcare landscape. Flaharty noted that after careful review, the council recommended the Innovative Technology contract to BD, underscoring the system’s alignment with Vizient’s goal of identifying technologies that can deliver real innovation to healthcare.

About Vizient’s Reach and Mission
Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non‑acute healthcare providers. Collectively, its members account for more than $156 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient leverages client‑led councils and task forces to evaluate emerging products. When a product demonstrates the potential to bring substantive innovation to healthcare, Vizient may award a contract outside the typical competitive bid cycle, as it did with CentroVena One™.

BD’s Company Profile
BD is one of the world’s largest pure‑play medical technology companies, guided by a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems, and interventional therapies. With more than 60,000 employees operating worldwide, BD develops transformative technologies, services, and solutions that optimize clinical operations and improve patient care. The company’s portfolio reaches billions of products annually, aiming to enhance outcomes, lower costs, increase clinical efficiency, improve safety, and expand access to healthcare. BD maintains active engagement with customers through collaboration, and it invites interested parties to learn more via its website (bd.com) or its social‑media channels on LinkedIn, X (@BDandCo), and Instagram (@becton_dickinson).

Study Context and Limitations
The press release includes a footnote clarifying that the efficiency comparisons (30 % fewer steps, 50 % reduction in maximum procedure time) are based on a head‑to‑head simulation study involving 49 participants, published in The Journal of Emergency Medicine in December 2025. BD notes that results from simulated environments may not fully reflect actual clinical performance, and real‑world outcomes could vary depending on patient anatomy, clinician experience, and institutional protocols.

Conclusion
The Vizient Innovative Technology contract awarded to BD’s CentroVena One™ Insertion System signals industry recognition of a device designed to simplify a traditionally complex and risky procedure. By integrating essential components into a single system, reducing procedural steps and time, and embedding safety features, the technology addresses both efficiency and safety concerns central to modern venous access practices. As BD prepares to roll out the system to a broader Vizient customer base, the innovation could influence how central lines are placed across a wide range of healthcare settings, potentially leading to shorter procedure times, fewer complications, and improved satisfaction for both patients and clinicians.

SignUpSignUp form

LEAVE A REPLY

Please enter your comment!
Please enter your name here